CYP19A1 and breast carcinoma: Third-generation aromatase inhibitors (AIs) have become the cornerstone of endocrine therapy for postmenopausal HR+ ​patients with breast cancer,2 demonstrating proven efficacy in suppressing estrogen production and reducing recurrence risk.3